Work

Intravenous immunoglobulin-induced eczematous dermatitis treated with dupilumab

Year: 2024

Type: article

Abstract: Intravenous immunoglobulin (IVIG) therapy is an effective treatment for immunodeficiency and autoimmune diseases. IVIG is well tolerated, with the most common adverse reaction being a transient flu-like illness. Rarely, severe adverse effects such as renal impairment and aseptic meningitis can occur. Adverse dermatological reactions are uncommon, with a reported incidence of 6%, which include urticaria, maculopapular rash, and desquamation.1 Rare cases of IVIG-associated eczematous reactions have also been reported in the literature.

Source: JAAD Case Reports

DOI: 10.1016/j.jdcr.2024.05.002

Authors: Katelyn Singh, Rachel Breidbart, Anjali Jaiswal, William Damsky, Keith A. Choate, Matthew Vesely

Institution: Yale University

Language: English

Topic: Dermatology and Skin Diseases

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $750